

Supporting Information

Site-Activated Chelators Targeting Acetylcholinesterase and Monoamine Oxidase for Alzheimer's Therapy

Hailin Zheng^{a,b}, Moussa B.H. Youdim^{c,1} and Mati Fridkin^{a,1}

Table of Contents:

1. Chemistry (S1-S2).

1.1. General.

1.2. Synthesis and characterization of 2 and 3.

2. Biology: (S2-S3).

2.1. Determination of inhibition of AChE and BChE activity.

2.2. Cytotoxicity Assays.

2.3. MTT Test.

2.4. Preparation of brain MAO.

2.5. Determination of MAO activity in vitro.


2.6. Prochelator Activation.

3. References (S3).

1. Chemistry


1.1. General: Starting materials for chemical synthesis were obtained from the following companies: Aldrich (USA), Merck (Germany), Fluka (Switzerland). HPLC grade acetonitrile and trifluoroacetic acid (TFA) were from JT Baker (Phillipsburg, NJ). Tetrahydrofuran (THF) was distilled over LiAlH_4 and passed through an Al_2O_3 column. NMR spectra were measured on a Bruker WH-270, a Bruker DPX-250, or a Bruker AMX-400 NMR spectrometer. Flash column chromatography separations were performed on silica gel Merck 60 (230-400 mesh ASTM). UV/VIS spectra were measured on a Hewlett-Packard 8450A diode array spectrophotometer. TLC was performed on E. Merck Kieselgel 60 F₂₅₄ plates. Staining of TLC plates was done by basic aqueous 1% KMnO_4 . Mass spectra (DI, EI-MS) were measured on a VG-platform-II electrospray single quadrupole mass spectrometry (Micro Mass, UK). The purifications were performed on a Spectra-Physics SP8800 HPLC system equipped with an Applied Biosystems 757 variable wavelength absorbance detector that was set to 254 nm. HPLC pre-packed columns were Vydac RP-18 column (250 × 22 mm; 10 μm bead size, Merck, Darmstadt, Germany) for preparative purifications and an RP-18, 100 mm × 4.6 mm Chromolith column (Merck) for purity determinations. All new compounds for biological studies have purity not less than 95%. The purification was achieved by using a linear gradient comprising 0.1% TFA in H_2O (solution A) and 0.1% TFA in 75% aqueous acetonitrile (solution B) with a flow of 10.0 mL/min over 50 min. The purified products were neutralized by 5% NaHCO_3 and extracted with dichloromethane or ethyl acetate to afford products as free base. Starting material **M30** was prepared as described previously (1).

1.2. Synthesis of new prochelators 2 and 3



Synthesis of 5-(N-methyl-N-propargylaminomethyl) quinolin-8-yl dimethyl

carbamate 2. To a stirred solution of **M30** (45 mg, 0.2 mmol), pyridine (97 μ L, 1.2 mmol) in anhydrous THF (1 mL) was added triphosgene (71 mg, 0.24 mmol) under argon atmosphere at 0 $^{\circ}$ C. After 0.5 h stirring at 0 $^{\circ}$ C, dimethylamine (1 N solution in THF) (0.24 mL, 0.22 mmol) was added, and the reaction mixture was stirred for 0.5 h at 0 $^{\circ}$ C and then 0.5 h at room temperature. After evaporation of the solvent, water was added and the resulting mixture was extracted with ethyl acetate. The combined organic extracts were washed with brine and dried with NaSO₄. Evaporation of the solvent gave a crude product that was purified by RP HPLC and characterized by LC-MS, H¹ NMR, and ¹³C NMR. (38 mg, 64 % yield, purity 97%). H¹ NMR (250 MHz, D₂O), 2.56 (s, 6H), 2.77 (m, 1H), 2.80 (s, 3H), 3.67 (s, 2H), 4.44 (s, 2H), 7.55 (d, J = 8.0 Hz, 1H), 7.80 (m, 2H), 8.79 (d, J=5.50 Hz, 1H), 9.06 (d, J=8.75 Hz, 1H). ¹³C NMR (63 MHz, hydrochloric salt in D₂O) 39.46, 39.51, 42.91, 47.98, 56.31, 74.14, 84.09, 126.33, 127.30, 129.33, 131.91, 134.95, 138.10, 146.04, 146.53, 148.35, 157.21. Mass Mass spectrometry: calculated for C₂₀H₂₃N₃O₂ m/z [M +H]⁺=298.35, found [M +H]⁺ = 298.53.




Current Data Parameters
 NAME H358 HPLC
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20060902
 Time 10.43
 INSTRUM spect
 PROBHD 5 mm QNP 1H/1
 PULPROG zg
 TD 16384
 SOLVENT D2O
 NS 30
 DS 0
 SWH 4990.020 Hz
 FIDRES 0.304567 Hz
 AQ 1.6417269 sec
 RG 45.3
 DW 100.200 usec
 DE 6.00 usec
 TE 300.0 K
 D1 1.00000000 sec
 MCREST 0.00000000 sec
 MCWRK 0.01500000 sec

===== CHANNEL f1 =====
 NUC1 1H
 P1 10.50 usec
 PL1 -6.00 dB
 SFO1 250.1310403 MHz

F2 - Processing parameters
 SI 32768
 SF 250.1300754 MHz
 WDW EM
 SSB 0
 LB 0.01 Hz
 GB 0
 PC 1.00



Current Data Parameters
 NAME H358 C HPL
 EXPNO 2
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20060902
 Time 11.04
 INSTRUM spect
 PROBHD 5 mm QNP 1H/1
 PULPROG zgdc
 TD 65536
 SOLVENT D2O
 NS 311
 DS 0
 SWH 18832.393 Hz
 FIDRES 0.287360 Hz
 AQ 1.7400308 sec
 RG 11585.2
 DW 26.550 usec
 DE 6.00 usec
 TE 300.0 K
 D1 2.00000000 sec
 d11 0.03000000 sec
 MCREST 0.00000000 sec
 MCWRK 0.01500000 sec


===== CHANNEL f1 =====
 NUC1 13C
 P1 6.00 usec
 PL1 -6.00 dB
 SFO1 62.9008936 MHz

===== CHANNEL f2 =====
 CPDPRG2 waltz16
 NUC2 1H
 PCPD2 100.00 usec
 PL2 120.00 dB
 PL12 14.00 dB
 SFO2 250.1310403 MHz

F2 - Processing parameters
 SI 32768
 SF 62.8950593 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.00

Synthesis of 5-(N-methyl-N-propargylaminomethyl) quinolin-8-yl ethylmethyl carbamate 3. 3 was synthesized by the method as described above for synthesis of **2**. Yield: 60%, purity 98%. ^1H NMR (250 MHz, D_2O), 0.80 (m, 3H), 2.57 (s 1H), 2.62 (s, 3H), 2.83 (s, 3H), 3.10 (m, 2H), 3.72 (s, 3H), 4.73 (s, 3H), 7.59 (d, $J = 8.0$ Hz, 1H), 7.90 (m, 2H), 8.86 (d, $J=5.25$ Hz, 1H), 9.13 (d, $J=8.75$ Hz, 1H). ^{13}C NMR (63 MHz, hydrochloric salt in D_2O) 14.08, 15.05, 36.83, 42.75, 47.40, 47.78, 56.08, 73.94, 84.02, 126.23, 127.03, 129.15, 131.73, 134.71, 137.99, 146.46, 148.21, 156.45. Mass spectrometry: calculated for $\text{C}_{18}\text{H}_{21}\text{N}_3\text{O}_2$ m/z $[\text{M} + \text{Na}]^+ = 334.38$, found $[\text{M} + \text{Na}]^+ = 334.51$.





2. Biology

2.1. Determination of inhibition of AChE and BChE activity: Ellman's method was adapted for determination of AChE and BuAChE activities in rat brain homogenates. Brain tissue from adult Wistar rats was homogenized at 2% w/v (or 10%, for butyrylcholinesterase) in 0.1 M sodium phosphate buffer, pH 7.4, with added NaCl 58.5 g/L and Triton X-100 0.05% v/v. Aliquots of homogenate (20 μ L) were incubated with HLA20A for designed time intervals in phosphate buffer pH 7.4 before addition of 5,5'-dithiobis(2-nitrobenzoic) acid and either 1 mM acetylthiocholine iodide or 10 mM butyrylthiocholine iodide (Sigma, St. Louis, MO). The reaction was run at 37 $^{\circ}$ C in a final volume of 200 μ L in 96-well microplates and was followed at 412 nm for 5 min with a plate reader. In every experiment, cholinesterase-independent (nonspecific) substrate hydrolysis was determined by including one experimental group treated with tacrine 30 μ M; appropriate tissue and reagent blanks were also included. Reaction velocities were determined in three or four replicates per condition; these were averaged and expressed as percent activity relative to control (solvent), after subtracting the rate of

nonspecific hydrolysis. Results are reported as mean (SEM of IC₅₀ obtained independently from three to five experiments).

2.2. Cytotoxicity Assays: Human SH-SY5Y neuroblastoma cells were plated in 100-mm culture dishes and cultured in DMEM (4,500 mg/l glucose), containing 10% FCS (fetal calf serum, Bet Haemek, Israel), and 1% of a mixture of penicillin/ streptomycin/ nystatin. When cells reached the required confluence, the culture medium was removed and the cells were detached by vigorous washing followed by centrifugation at 200 g for 5 min. The cells (0.5×10^4 cells/well) in DMEM with 10% of fetal calf serum, were placed in microtiter plates (96 wells) precoated with collagen (10 mg/cm²). The cells were allowed to attach for 24 h before drugs were added. The cell viability was tested by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assays (see below) after 48 h incubation.

2.3. MTT Test: The MTT test is based on the conversion of MTT to blue formazan crystals by viable cells. Briefly, 24 h after treatment, the medium was removed and replaced with a medium (100 µl/well) lacking serum. To each well, 10 µl of a 5 mg/ml MTT solution in PBS was added. After incubation at 37 °C for 2 h, 100 µl of 10% SDS in 0.01N HCl was added and the solution was mixed thoroughly and incubated for additional 24 h. Absorption was determined in a Perkin-Elmer Dual Wave-length Eliza-Reader at $\lambda = 570$ nm/650 nm after automatic subtraction of background readings. Cell viability was expressed as a percentage of cells untreated with 6-hydroxydopamine, which served as the control group and was designated as 100%. The results are expressed as percentage of the control.

2.4. Preparation of brain MAO. Rats were decapitated and the brains were quickly taken into a weighted ice-cold sucrose buffer (10 mM Tris-HCl buffer, pH 7.4 containing 0.32 M sucrose), and their weights were measured. The brains were homogenized at 0–4°C in 0.32 M sucrose (one part tissue to 20 parts sucrose) in a Teflon glass homogenizer. The resultant homogenates were used to determine MAO activity. Protein concentration was determined with Bradford reagent at 595 nm, using bovine serum albumin as a standard.

2.5. Determination of MAO activity in vitro. The activity of MAO-A and MAO-B were determined by the adapted method of Tipton & Youdim (Tipton et al. 1983). Briefly, the tested drug was added to a suitable dilution of the enzyme preparation (70 µg protein for MAO-B and 150 µg for MAO-A assay) in 0.05 M phosphate buffer (pH 7.4). The mixture was incubated together with 0.05 µM l-deprenyl, a specific inhibitor of MAO-B (for determination of MAO-A) or 0.05 µM clorgyline a specific inhibitor of MAO-A (for determination of MAO-B). Incubation was carried on 1 hour at 37°C before addition of ¹⁴C-5-hydroxytryptamine binoxalate (100 µM) for determination of MAO-A, or ¹⁴C-phenylethylamine 100 µM for determination of MAO-B activity, and incubation continued for 30 min or 20 min, respectively. The reaction was stopped with 2 M ice-cold citric acid, and the radioactive metabolites (5-hydroxytryptaldehyde and phenylacetaldehyde) were extracted by addition of 2 ml of ethylacetate/toluene (1:1 vol/vol). The radioactivity contained in the organic phase was determined by liquid-scintillation counting in cpm units.

2.6. Prochelator Activation: For experiments for activating **2**, AChE from *Electrophorus electricus* (electric eel) (Sigma Company) was used. **2** was incubated with an excess of AChE in 0.1 M sodium phosphate buffer, pH 7.4, containing NaCl 58.5 g/L and Triton X-100 0.05% v/v for 1 h. The metabolite (**M30**) was extracted from the mixture using ethyl acetate and after removal of the solvent and drying under vacuum, was re-dissolved in 5%NH₄Ac (pH = 7). UV/VIS spectra were measured on a Hewlett-Packard 8450A diode array spectrophotometer. The absorption spectra were recorded at room temperature in 1-cm quartz cells, with 5%NH₄Ac (pH = 7) as the reference in the absence and presence of FeSO₄, CuSO₄ or ZnCl₂ (0.1 mM).

3. References

1. Zheng, H., Weiner, L.M., Bar-Am, O., Epsztejn, S., Cabantchik, Z.I., Warshawsky, A., Youdim, M.B., and Fridkin, M. (2005). Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. *Bioorg. Med. Chem.* 13, 773-783.